Sublingual transmucosal delivery of organic nitrates: Treatment of angina pectoris

John Anthony Bauer, Jennifer L. Seifert

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations

Abstract

In 1879 Sir William Murrell published a seminal report demonstrating the effectiveness of lingual nitroglycerin (NTG) for patients suffering from acute chest pain (angina pectoris) (1). Because bloodletting of patients in this era was not uncommon as “therapy” for these angina symptoms, this discovery of a reliable pharmacological approach was a significant therapeutic advance. Much later, in the 1960s, sublingual NTG tablets were made commercially available in the United States. Interestingly, despite numerous advances in cardiovascular medicine, sublingual NTG remains the drug of choice for the pharmacological treatment of acute angina episodes and for the prevention of angina (2,3).

Original languageEnglish
Title of host publicationDrug Delivery to the Oral Cavity
Subtitle of host publicationMolecules to Market
Pages111-124
Number of pages14
ISBN (Electronic)9780849398513
StatePublished - Jan 1 2005

Bibliographical note

Publisher Copyright:
© 2005 by Taylor & Francis Group, LLC.

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • General Medicine

Fingerprint

Dive into the research topics of 'Sublingual transmucosal delivery of organic nitrates: Treatment of angina pectoris'. Together they form a unique fingerprint.

Cite this